Sunday, November 4, 2012

New Road Map for Clinical Trials Using iPS Cells


I have been excited at Prof. Yamanaka’s winning of Nobel Prize in Physiology or Medicine. It is not only me. Everyone in Japan has been excited and encouraged. His award gives us a hope even in such a prolonged depression, making me feel like writing about iPS cells.

The Ministry of Education, Culture, Sports, Science and Technology announced Friday a new road map showing target times to practically use induced pluripotent stem cells (iPS cells).

The road map, established in 2009 for the first time, has been revised due to advance in research. In addition to renewal of a targeted timing to kick off clinical trials, the new map aims to establish technologies to create three-dimensional organs with tissue structures for the liver and the cornea within five years and for the kidney and the lung within ten years.

Advanced research in creating organs in the past three years has already brought a report of generation of the retina and the pituitary gland with 3-D structures.

Concerning clinical trials, goals have been set for 14 stages including a practical application of retinal cells derived from iPS cells to age-related macular degeneration treatments, being accelerated about two years earlier in research to generate red blood cells. Also in the planned iPS cells storage and supply center, “iPS cells stock,” led by Center for iPS Cell Research and Application of Kyoto University, the revised road map showed that the facility will establish the stock within two years and begin supplying iPS cells and their derivatives in two to three years.

1 comment:

  1. Congratulations on posting the first article! Yes, Professor Yamanaka's astonishing work has certainly cheered us up. We really hope that these advanced technology will be put into practical use in the very near future for people around the globe.

    ReplyDelete